Home LiteratureArticle Details
PMID: 10397535 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection.

AIDS (London, England) ·Vol. 13 ·No. 9 ·1999-06-18 ·Pages 1051-61

Staprans S, Marlowe N, Glidden D, Novakovic-Agopian T, Grant RM, Heyes M, Aweeka F, Deeks S, Price RW

Abstract

To compare the kinetics and magnitude of HIV-1 RNA responses to antiretroviral therapy (ART) in the cerebrospinal fluid (CSF) and plasma. Repeated lumbar punctures (LPs) were performed after the initiation or change in ART in 15 HIV-1-infected subjects, with the focus on two phases of response: an acute phase within the first 11 days, for which crude estimates of viral RNA half-lives and decay rates were derived and CSF:plasma relative decay ratios quantitatively analysed; and a longer-term phase beyond 4 weeks that was descriptively assessed. In 13 subjects studied during the acute phase, the crude HIV-1 RNA half-life was longer (median 2.0 compared with 1.9 days), the decay rate slower (median 0.13 compared with 0.16 log10 copies/day) and, most notably, the variability greater (intraquartile range of half-life 1.8-4.3 compared with 1.7-2.1 days) in the CSF than in the plasma. A slower decay in the CSF correlated with lower initial blood CD4 T lymphocyte counts (P = 0.001). Seven of 11 subjects studied at 4 weeks or later, including some with slower acute-phase CSF responses, showed greater or more durable viral suppression in the CSF. Divergent acute-phase viral kinetics in the CSF and plasma, and proportionally greater long-term decrements in CSF HIV-1 RNA in slow early-responders or poor overall plasma responders indicate variable compartmentalization of CSF infection, consistent with a model of two prototypes of CSF infection: short-lived, transitory infection that predominates in early HIV-1 infection and longer-lived, more autonomous CSF infection predominating in late HIV-1 infection. Additional studies will be needed to define more precisely the acute and longer-term CSF kinetics in different clinical settings and to assess this model.

MeSH Terms
AIDS Dementia Complex/drug therapy,virology Adult Anti-HIV Agents/therapeutic use CD4 Lymphocyte Count Drug Therapy, Combination HIV Protease Inhibitors/therapeutic use HIV-1/physiology Humans Male Quinolinic Acid/blood RNA, Viral/blood,cerebrospinal fluid Reverse Transcriptase Inhibitors/therapeutic use Time Factors Treatment Outcome Viral Load
Chemicals
Anti-HIV Agents HIV Protease Inhibitors RNA, Viral Reverse Transcriptase Inhibitors Quinolinic Acid
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Staprans S
Department of Medicine, University of California, San Francisco, USA.
Marlowe N
Glidden D
Novakovic-Agopian T
Grant R M
Heyes M
Aweeka F
Deeks S
Price R W
Article Info
Journal
AIDS (London, England)
Abbr.
AIDS
ISSN
0269-9370
Published
1999-06-18
Pages
1051-61
Language
English
Region
England
NLM ID
8710219
Subset
IM
Grants
NCRR NIH HHS · 5-MO1-RR-00083-36 · United States
NIAID NIH HHS · P30 AI27763 · United States
NINDS NIH HHS · R01 NS37660 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com